Fulcrum Therapeutics Inc Stock

$7.83

2.25% yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US3596161097

Symbol

FULC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Fulcrum Therapeutics Inc Stock price

$7.83

-10.60 57.51% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

-0.18 2.25%

ISIN

US3596161097

Symbol

FULC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$422.7m

Enterprise Value

$196.1m

Net debt

positive

Cash

$226.6m

Shares outstanding

54.0m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

25.9

P/B

1.9

Financial Health

Equity Ratio

93.2%

Return on Equity

-4.0%

ROCE

ROIC

Debt/Equity

0.0

Financials (TTM | estimate)

Revenue

- | $0.0

EBITDA

- | $-87.2m

EBIT

- | $-85.2m

Net Income

- | $-64.3m

Free Cash Flow

$7.6m

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Fulcrum Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Fulcrum Therapeutics Inc forecast:

9x Buy

69%

3x Hold

23%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Fulcrum Therapeutics Inc forecast:

Buy

69%

Hold

23%

Sell

Analyst Estimates with Stock Price Targets

Financial data from Fulcrum Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	80 80	2,747% 2,747% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	36 36	13% 13% 46%
- Research and Development Expense	63 63	12% 12% 79%
EBITDA	-18 -18	83% 83% -23%
- Depreciation and Amortization	1.59 1.59	27% 27% 2%
EBIT (Operating Income) EBIT	-20 -20	82% 82% -25%
Net Profit	-9.73 -9.73	90% 90% -12%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Fulcrum Therapeutics Inc Stock News

Neutral

GlobeNewsWire

●

about 22 hours ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the com...

Neutral

GlobeNewsWire

●

about one month ago

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 06, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the com...

Neutral

GlobeNewsWire

●

about one month ago

Fulcrum Therapeutics to Present at Upcoming Medical Meetings

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced upcoming presentations at the 5th Global Congress on Sickle Cell Disease and the 2025 European Hematology Associatio...

More Fulcrum Therapeutics Inc News

Company Profile

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.

Head office	United States
CEO	Alexander Sapir
Employees	45
Founded	2015
Website	www.fulcrumtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now